© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
Cabometyx is the third liver cancer drug approved in the past six months.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
